HQY
$69.05
Healthequity
($1.54)
(2.18%)
Earnings Details
2nd Quarter July 2022
Tuesday, September 06, 2022 4:01:00 PM
Tweet Share Watch
Summary

Healthequity Misses

Healthequity (HQY) reported 2nd Quarter July 2022 earnings of $0.32 per share on revenue of $206.1 million. The consensus earnings estimate was $0.33 per share on revenue of $203.8 million. The Earnings Whisper number was $0.35 per share. Revenue grew 9.0% on a year-over-year basis.

The company said it continues to expect fiscal 2023 non-GAAP earnings of $1.23 to $1.32 per share but now expects revenue of $834.0 million to $844.0 million. The company's previous guidance was revenue of $827.0 million to $837.0 million and the current consensus earnings estimate is $1.28 per share on revenue of $831.40 million for the year ending January 31, 2023.

HealthEquity Inc is a technology-enabled services platform that empowers consumers to make healthcare saving and spending decisions.

Results
Reported Earnings
$0.32
Earnings Whisper
$0.35
Consensus Estimate
$0.33
Reported Revenue
$206.1 Mil
Revenue Estimate
$203.8 Mil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

HealthEquity Reports Second Quarter Ended July 31, 2022 Financial Results

Highlights of the second quarter include:

  • Revenue of $206.1 million, an increase of 9% compared to $189.1 million in Q2 FY22.
  • Net loss of $10.7 million, compared to $3.8 million in Q2 FY22, with non-GAAP net income of $28.1 million, a decrease of 16% compared to $33.4 million in Q2 FY22.
  • Net loss per diluted share of $0.13, compared to $0.05 in Q2 FY22, with non-GAAP net income per diluted share of $0.33, compared to $0.40 in Q2 FY22.
  • Adjusted EBITDA of $67.0 million, an increase of 2% compared to $65.5 million in Q2 FY22.
  • 7.5 million HSAs, an increase of 26% compared to Q2 FY22.
  • Total HSA Assets of $20.5 billion, an increase of 33% compared to Q2 FY22.
  • 14.5 million Total Accounts, including both HSAs and complementary CDB accounts, an increase of 11% compared to Q2 FY22.

DRAPER, Utah, Sept. 06, 2022 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") non-bank custodian, today announced financial results for its second quarter ended July 31, 2022.

"Team Purple opened a record 196,000 new HSAs in Q2 and grew Total HSA Assets 33% year-over-year to an industry-leading $20.5 billion," said Jon Kessler, President and CEO of HealthEquity. "Sales momentum, macro tailwinds, and a team focused on remarkable service position us for strong results in fiscal 2023 and beyond."

Second quarter financial results

Revenue for the second quarter ended July 31, 2022 was $206.1 million, an increase of 9% compared to $189.1 million for the second quarter ended July 31, 2021. Revenue this quarter included: service revenue of $103.0 million, custodial revenue of $65.6 million, and interchange revenue of $37.5 million.

HealthEquity reported a net loss of $10.7 million, or $0.13 per diluted share, and non-GAAP net income of $28.1 million, or $0.33 per diluted share, for the second quarter ended July 31, 2022. The Company reported a net loss of $3.8 million, or $0.05 per diluted share, and non-GAAP net income of $33.4 million, or $0.40 per diluted share, for the second quarter ended July 31, 2021.

Adjusted EBITDA was $67.0 million for the second quarter ended July 31, 2022, an increase of 2% compared to the second quarter ended July 31, 2021. Adjusted EBITDA was 33% of revenue, compared to 35% for the fiscal quarter ended July 31, 2021.

Account and asset metrics

HealthEquity reported sales of 196,000 new HSAs in the second quarter ended July 31, 2022, compared to 180,000 in the second quarter ended July 31, 2021. HSAs as of July 31, 2022 were 7.5 million, an increase of 26% year over year, including 516,000 HSAs with investments, an increase of 28% year over year. Total Accounts as of July 31, 2022 were 14.5 million, including 7.0 million other consumer-directed benefits ("CDBs").

Total HSA Assets as of July 31, 2022 were $20.5 billion, an increase of 33% year over year. Total HSA Assets included $13.1 billion of HSA cash and $7.4 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.8 billion as of July 31, 2022.

Business outlook

For the fiscal year ending January 31, 2023, management expects revenues of $834 million to $844 million. Its outlook for net loss is between $43 million and $36 million, resulting in net loss of $0.51 to $0.43 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $103 million and $111 million, resulting in non-GAAP net income per diluted share of $1.23 to $1.32 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $252 million to $262 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Tuesday, September 6, 2022 to discuss the second quarter 2023 financial results. A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

  • Adjusted EBITDA is adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
  • Non-GAAP net income is calculated by adding back to GAAP net income (loss) before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
  • Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for our more than 14 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

  • the impact of societal and economic changes arising out of the COVID-19 pandemic on the Company, its operations and its financial results;
  • our ability to realize the anticipated financial and other benefits from combining the operations of recent and future acquisitions with our business successfully;
  • our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
  • our dependence on the continued availability and benefits of tax-advantaged health savings accounts and other consumer-directed benefits;
  • our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
  • the significant competition we face and may face in the future, including from those with greater resources than us;
  • our reliance on the availability and performance of our technology and communications systems;
  • potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
  • the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
  • our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
  • our reliance on partners and third-party vendors for distribution and important services;
  • our ability to develop and implement updated features for our technology and communications systems and successfully manage our growth;
  • our ability to protect our brand and other intellectual property rights; and
  • our reliance on our management team and key team members.

For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2022, our Quarterly Report on Form 10-Q for the quarter ended April 30, 2022, and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact
Richard Putnam
801-727-1209
rputnam@healthequity.com

HealthEquity, Inc. and its subsidiaries
Condensed consolidated balance sheets

(in thousands, except par value)July 31, 2022 January 31, 2022
 (unaudited)  
Assets   
Current assets   
Cash and cash equivalents$176,886 $225,414
Accounts receivable, net of allowance for doubtful accounts of $6,215 and $6,228 as of July 31, 2022 and January 31, 2022, respectively 90,426  87,428
Other current assets 41,274  38,495
Total current assets 308,586  351,337
Property and equipment, net 18,028  23,372
Operating lease right-of-use assets 60,588  63,613
Intangible assets, net 991,945  973,137
Goodwill 1,645,999  1,645,836
Other assets 48,878  49,807
Total assets$3,074,024 $3,107,102
Liabilities and stockholders’ equity   
Current liabilities   
Accounts payable$15,841 $27,541
Accrued compensation 41,989  47,136
Accrued liabilities 43,287  57,589
Current portion of long-term debt 13,125  8,750
Operating lease liabilities 11,275  12,171
Total current liabilities 125,517  153,187
Long-term liabilities   
Long-term debt, net 914,966  922,077
Operating lease liabilities, non-current 62,626  65,232
Other long-term liabilities 13,731  14,185
Deferred tax liability 92,288  99,846
Total long-term liabilities 1,083,611  1,101,340
Total liabilities 1,209,128  1,254,527
Commitments and contingencies   
Stockholders’ equity   
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2022 and January 31, 2022, respectively   
Common stock, $0.0001 par value, 900,000 shares authorized, 84,526 and 83,780 shares issued and outstanding as of July 31, 2022 and January 31, 2022, respectively 8  8
Additional paid-in capital 1,713,122  1,676,508
Accumulated earnings 151,766  176,059
Total stockholders’ equity 1,864,896  1,852,575
Total liabilities and stockholders’ equity$3,074,024 $3,107,102

HealthEquity, Inc. and its subsidiaries
Condensed consolidated statements of operations and comprehensive loss (unaudited)

 Three months ended July 31, Six months ended July 31,
(in thousands, except per share data) 2022   2021   2022   2021 
Revenue       
Service revenue$103,034  $109,182  $207,382  $211,716 
Custodial revenue 65,599   48,776   124,964   95,754 
Interchange revenue 37,509   31,145   79,475   65,835 
Total revenue 206,142   189,103   411,821   373,305 
Cost of revenue       
Service costs 74,914   67,334   155,788   137,966 
Custodial costs 7,090   4,824   13,731   9,833 
Interchange costs 6,326   4,974   13,317   10,419 
Total cost of revenue 88,330   77,132   182,836   158,218 
Gross profit 117,812   111,971   228,985   215,087 
Operating expenses       
Sales and marketing 15,843   15,476   32,403   29,562 
Technology and development 46,580   37,898   91,763   73,367 
General and administrative 25,937   22,812   49,664   43,499 
Amortization of acquired intangible assets 24,181   20,289   47,879   40,103 
Merger integration 7,683   16,371   16,977   25,178 
Total operating expenses 120,224   112,846   238,686   211,709 
Income (loss) from operations (2,412)  (875)  (9,701)  3,378 
Other expense       
Interest expense (11,493)  (7,254)  (21,954)  (13,943)
Other income (expense), net 32   344   (269)  (3,286)
Total other expense (11,461)  (6,910)  (22,223)  (17,229)
Loss before income taxes (13,873)  (7,785)  (31,924)  (13,851)
Income tax benefit (3,219)  (3,967)  (7,631)  (7,418)
Net loss and comprehensive loss$(10,654) $(3,818) $(24,293) $(6,433)
Net loss per share:       
Basic$(0.13) $(0.05) $(0.29) $(0.08)
Diluted$(0.13) $(0.05) $(0.29) $(0.08)
Weighted-average number of shares used in computing net loss per share:       
Basic 84,443   83,481   84,236   82,628 
Diluted 84,443   83,481   84,236   82,628 

HealthEquity, Inc. and its subsidiaries
Condensed consolidated statements of cash flows (unaudited)

 Six months ended July 31,
(in thousands) 2022   2021 
Cash flows from operating activities:   
Net loss$(24,293) $(6,433)
Adjustments to reconcile net loss to net cash provided by operating activities:   
Depreciation and amortization 80,226   64,819 
Stock-based compensation 32,140   28,416 
Amortization of debt discount and issuance costs 1,639   2,482 
Change in fair value of contingent consideration    1,011 
Other non-cash items 269   (752)
Deferred taxes (7,558)  (4,051)
Changes in operating assets and liabilities:   
Accounts receivable, net (3,161)  (230)
Other assets (1,546)  20,636 
Operating lease right-of-use assets 4,117   6,060 
Accrued compensation (4,973)  (10,639)
Accounts payable, accrued liabilities, and other current liabilities (25,586)  (30,213)
Operating lease liabilities, non-current (3,594)  (4,556)
Other long-term liabilities (454)  1,616 
Net cash provided by operating activities 47,226   68,166 
Cash flows from investing activities:   
Purchases of software and capitalized software development costs (24,215)  (32,097)
Purchases of property and equipment (2,384)  (6,352)
Acquisition of intangible member assets (68,725)  (2,653)
Acquisitions, net of cash acquired    (49,533)
Proceeds from sale of equity securities    2,367 
Net cash used in investing activities (95,324)  (88,268)
Cash flows from financing activities:   
Principal payments on long-term debt (4,375)  (15,625)
Settlement of client-held funds obligation, net (991)  (2,636)
Proceeds from exercise of common stock options 4,936   6,672 
Proceeds from follow-on equity offering, net of payments for offering costs    456,642 
Net cash provided by (used in) financing activities (430)  445,053 
Increase (decrease) in cash and cash equivalents (48,528)  424,951 
Beginning cash and cash equivalents 225,414   328,803 
Ending cash and cash equivalents$176,886  $753,754 

HealthEquity, Inc. and its subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)

 Six months ended July 31,
(in thousands) 2022  2021 
Supplemental cash flow data:   
Interest expense paid in cash$19,450 $9,838 
Income tax payments (refunds), net 573  (5,545)
Supplemental disclosures of non-cash investing and financing activities:   
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation 5,040  4,077 
Purchases of property and equipment included in accounts payable or accrued liabilities 356  357 
Purchases of intangible member assets included in accounts payable or accrued liabilities 1,849   
Contingent consideration recognized at acquisition   8,147 
Exercise of common stock options receivable 8  119 
Increase in goodwill due to measurement period adjustments, net 163   

Stock-based compensation expense (unaudited)

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss is as follows:

 Three months ended July 31, Six months ended July 31,
(in thousands) 2022  2021  2022  2021
Cost of revenue$3,998 $3,068 $7,005 $5,471
Sales and marketing 2,553  2,660  4,567  4,848
Technology and development 2,963  3,693  6,343  6,706
General and administrative 8,640  6,196  14,225  11,391
Other expense, net (1)       342
Total stock-based compensation expense$18,154 $15,617 $32,140 $28,758

(1)   Equity-based awards exchanged for cash in connection with the Luum acquisition.

Total Accounts (unaudited)

(in thousands, except percentages)July 31, 2022 July 31, 2021 % Change January 31, 2022
HSAs7,523 5,972 26% 7,207
New HSAs from sales - Quarter-to-date196 180 9% 472
New HSAs from sales - Year-to-date355 295 20% 918
New HSAs from acquisitions - Year-to-date90  n/a 740
HSAs with investments516 402 28% 455
CDBs7,023 7,171 (2)% 7,192
Total Accounts14,546 13,143 11% 14,399
Average Total Accounts - Quarter-to-date14,497 13,358 9% 14,326
Average Total Accounts - Year-to-date14,462 13,114 10% 13,450

HSA Assets (unaudited)

(in millions, except percentages)July 31, 2022 July 31, 2021 % Change January 31, 2022
HSA cash$13,097 $10,028 31% $12,943
HSA investments 7,441  5,443 37%  6,675
Total HSA Assets 20,538  15,471 33%  19,618
Average daily HSA cash - Year-to-date 12,924  10,007 29%  10,579
Average daily HSA cash - Quarter-to-date 12,941  9,963 30%  12,118

Client-held funds (unaudited)

(in millions, except percentages)July 31, 2022 July 31, 2021 % Change January 31, 2022
Client-held funds$801 $810 (1)% $897
Average daily Client-held funds - Year-to-date 852  876 (3)%  842
Average daily Client-held funds - Quarter-to-date 839  853 (2)%  822

Reconciliation of net loss to Adjusted EBITDA (unaudited)

 Three months ended July 31, Six months ended July 31,
(in thousands) 2022   2021   2022   2021 
Net loss$(10,654) $(3,818) $(24,293) $(6,433)
Interest income (89)  (533)  (141)  (941)
Interest expense 11,493   7,254   21,954   13,943 
Income tax benefit (3,219)  (3,967)  (7,631)  (7,418)
Depreciation and amortization 16,559   12,762   32,347   24,716 
Amortization of acquired intangible assets 24,181   20,289   47,879   40,103 
Stock-based compensation expense 18,154   15,617   32,140   28,416 
Merger integration expenses 7,683   16,371   16,977   25,178 
Acquisition costs (1) 47   1,665   53   7,604 
Gain on equity securities    (1,677)     (1,677)
Amortization of incremental costs to obtain a contract 1,074   1,352   2,142   2,624 
Costs associated with unused office space 1,313      2,607    
Other 501   200   1,345   (1,625)
Adjusted EBITDA$67,043  $65,515  $125,379  $124,490 

(1)   For the six months ended July 31, 2021, acquisition costs included $0.3 million of stock-based compensation expense.

Reconciliation of net loss outlook to Adjusted EBITDA outlook (unaudited)

 Outlook for the year ending
(in millions)January 31, 2023
Net loss$(43) - (36)
Interest expense46
Income tax benefit(15) - (12)
Depreciation and amortization64
Amortization of acquired intangible assets97
Stock-based compensation expense67
Merger integration expenses27
Amortization of incremental costs to obtain a contract4
Costs associated with unused office space5
Adjusted EBITDA$252 - 262

Reconciliation of net loss to non-GAAP net income (unaudited)

 Three months ended July 31, Six months ended July 31,
(in thousands, except per share data) 2022   2021   2022   2021 
Net loss$(10,654) $(3,818) $(24,293) $(6,433)
Income tax benefit (3,219)  (3,967)  (7,631)  (7,418)
Loss before income taxes - GAAP (13,873)  (7,785)  (31,924)  (13,851)
Non-GAAP adjustments:       
Amortization of acquired intangible assets 24,181   20,289   47,879   40,103 
Stock-based compensation expense 18,154   15,617   32,140   28,416 
Merger integration expenses 7,683   16,371   16,977   25,178 
Acquisition costs 47   1,665   53   7,604 
Gain on equity securities    (1,677)     (1,677)
Costs associated with unused office space 1,313      2,607    
Total adjustments to loss before income taxes - GAAP 51,378   52,265   99,656   99,624 
Income before income taxes - Non-GAAP 37,505   44,480   67,732   85,773 
Income tax provision - Non-GAAP (1) 9,376   11,120   16,933   21,443 
Non-GAAP net income 28,129   33,360   50,799   64,330 
        
Diluted weighted-average shares 84,443   83,481   84,236   82,628 
Non-GAAP net income per diluted share$0.33  $0.40  $0.60  $0.78 

(1)   The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

Reconciliation of net loss outlook to non-GAAP net income outlook (unaudited)

 Outlook for the year ending
(in millions, except per share data)January 31, 2023
Net loss$(43) - (36)
Income tax benefit(15) - (12)
Loss before income taxes - GAAP(58) - (48)
Non-GAAP adjustments: 
Amortization of acquired intangible assets97
Stock-based compensation expense67
Merger integration expenses27
Costs associated with unused office space5
Total adjustments to loss before income taxes - GAAP196
Income before income taxes - Non-GAAP138 - 148
Income tax provision - Non-GAAP (1)35 - 37
Non-GAAP net income$103 - 111
  
Diluted weighted-average shares84
Non-GAAP net income per diluted share (2)$1.23 - 1.32

(1)   The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

(2)   Non-GAAP net income per diluted share may not calculate due to rounding of non-GAAP net income and diluted weighted-average shares.

Certain terms

TermDefinition
HSAA financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.
CDBConsumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.
HSA memberConsumers with HSAs that we serve.
Total HSA AssetsHSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments in mutual funds through our custodial investment fund partner.
ClientOur employer clients.
Total AccountsThe sum of HSAs and CDBs on our platforms.
Client-held fundsDeposits held on behalf of our Clients to facilitate administration of our CDBs.
Network PartnerOur health plan partners, benefits administrators, and retirement plan recordkeepers.
Adjusted EBITDAAdjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
Non-GAAP net incomeCalculated by adding back to GAAP net income (loss) before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
Non-GAAP net income per diluted shareCalculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.


Primary Logo

Source: HealthEquity, Inc.